4-ARYL-2-ANILINO-PYRIMIDINES

The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have th...

Full description

Saved in:
Bibliographic Details
Main Authors BONNET PASCAL GHISLAIN ANDRE, VAN EMELEN KRISTOF, ANTONIUS BUIJNSTERS PETER JACOBUS JOHANNES, VERDONCK MARC GUSTAAF CELINE
Format Patent
LanguageEnglish
Published 28.02.2013
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to compounds of Formula (Ia) or (Ib), the N-oxide forms, pharmaceutically acceptable addition salts, quaternary amines, stereoisomers, tautomers, racemics, metabolites, prodrugs, hydrates, or solvates thereof, wherein Y1, m, n, R1; X1; X2; R2; X3; X4; R3; and R4 have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in therapy. The invention particularly relates to compounds that are kinase inhibitors useful for the treatment of disease states mediated by kinase, especially PLK4, in particular such compounds that are useful in the treatment of pathological processes which involve an aberrant cellular proliferation, such as tumor growth, rheumatoid arthritis, restenosis and atherosclerosis.
Bibliography:Application Number: US201213652721